McMaster receives $1.8M in funding for COVID-19 research

Gerry Wright and Karen Mossman have two of 49 projects across Canada that have been allocated a total of $25 million in funding from the Canadian Institutes of Health Research.

By Tina Depko, Health Sciences March 20, 2020

Experts Featured In This Story

Karen Mossman
Karen Mossman

Professor

See Profile
Gerard Wright
Gerard Wright

Scientific Director

See Profile

Two senior researchers of McMaster’s Faculty of Health Sciences have received a combined $1.8 million in funding to support new research projects to help combat COVID-19.

Gerry Wright and Karen Mossman have two of 49 projects across Canada that have been allocated a total of $25 million in funding from the Canadian Institutes of Health Research (CIHR).

Wright is a professor of biochemistry and biomedical sciences. He’s also the director of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR). He received $983,000 for a therapeutics project focused on targeting genetic and chemical vulnerabilities of novel coronavirus SARS-CoV-2.

“Our project will identify new therapeutic strategies that may help to treat COVID-19 patients,” reads the project description. “These strategies will also help mitigate newly emergent coronavirus-associated diseases that will undoubtedly continue to cause outbreaks in the future.”

Mossman is a professor of pathology and molecular medicine, and a member of the McMaster Immunology Research Centre. She’s also the acting vice-president, research for the university. She received $788,000 for a transmission dynamics and animal host project that focuses on SARS-CoV-2 pathogenesis in human and bat cells, and development of in vitro and in vivo infection models

“Bats have been shown to carry a diversity of viruses including coronaviruses globally, without showing signs of disease,” according to the description of her research. “Also, major circulating and endemic coronaviruses that are causing disease in humans are speculated to have evolved in bats.”

Earlier this month, Prime Minister Justin Trudeau announced a $275 million investment in Canadian research and development, as part of the country’s COVID-19 response. This includes research on medical countermeasures, including antivirals, vaccine development and support for clinical trials. To date, the federal government has distributed $51.8M to 96 research teams from across Canada.

Patty Hajdu, federal minister of health, said: “The outbreak of COVID-19 evolves quickly, and protecting the health of Canadians is our priority.

“The additional teams of researchers receiving funding today will help Canada quickly generate the evidence we need to contribute to the global understanding of the COVID-19 illness. Their essential work will contribute to the development of effective vaccines, diagnostics, treatments, and public health responses.”

Four people in white lab coats with stethoscopes around their shoulders stand in a row with their arms crossed. Their faces are not visible.

New study finds female family doctors spend more time caring for patients, yet earn less

Researchers found female family physicians spend 15 to 20 per cent more time per patient encounter than their male colleagues across a broad range of services.
Two scientists in conversation in a laboratory setting. One is holding a 3D-printed model of the antibiotic molecule they discovered.

How bacteria produce antibiotics without harming themselves 

McMaster researchers have figured out how a pathogen destroys its competitors while staying unaffected, offering a critical insight into the evolution of antibiotic resistance. 
Three scientists standing together in a laboratory. Two are holding small bottles.

New drug candidate reverses metabolic liver disease and fibrosis, pre-clinical data shows

The findings point to a potential new treatment for millions of people, addressing a critical gap where no approved drugs exist in Canada.